Clinical trial
A Multi-center, Randomized, Double-blind, Placebo Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A)
NCT04762758 is registered in ClinicalTrials.gov with Pharnext S.C.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Randomized, Double-blind, Placebo Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A)
- Lead sponsor
- Pharnext S.C.A.
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- March 30, 2021
- Completion date
- April 19, 2024
- Enrollment
- 350 (estimated)
- Sites
- 50
Conditions
As the registry lists them; a condition with its own page is linked.